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Mini Abstract 
A randomised clinical trial comparing simultaneous endovenous ablation and 
phlebectomy with endovenous ablation and delayed phlebectomy successfully recruited 
and treated 101 patients.  Combined endovenous ablation and phlebectomy delivers 
improved clinical outcomes and a reduced rate of need for further procedures, in 
addition to early Quality of Life improvements.  
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Abstract 
Objective 
A randomised clinical trial assessing the difference in quality of life and clinical 
outcomes between delayed and simultaneous phlebectomies in the context of 
endovenous truncal vein ablation 
Summary 
Endovenous ablation has replaced open surgery as the treatment of choice for 
truncal varicose veins.  Timing of varicosity treatment is controversial with delayed and 
simultaneous pathways having studies advocating their benefits.  A previous small 
randomised study has shown improved outcomes for simultaneous treatment. 
Methods 
Patients undergoing local anaesthetic endovenous thermal ablation were 
randomised to either simultaneous phlebectomy or delayed varicosity treatment.  Patients 
were reviewed at 6 weeks, 6 months and 1 year with clinical and quality of life scores 
completed, and were assessed at 6 weeks for need for further varicosity intervention, 
which was completed with either ultrasound guided foam sclerotherapy or local 
anaesthetic phlebectomy.  Duplex ultrasound assessment of the treated trunk was 
completed at 6 months. 
Structured Abstract
Results 
101 patients were successfully recruited and treated out of 221 suitable patients 
from a screened population of 393.  Patients in the simultaneous group (n=51) showed a 
significantly improved VCSS at all time points, 36% of the delayed group required 
further treatment compared to 2% of the simultaneous group (p<0.001).  There were no 
DVTs, with 1 SVT in each group. 
Conclusion 
Combined endovenous ablation and phlebectomy delivers improved clinical 
outcomes and a reduced need for further procedures, as well as early quality of life 
improvements.  
  
Ambulatory Varicosity avUlsion Later or Synchronised (AVULS): A 
Randomised Clinical Trial 
Tristan R A Lane1, Damian Kelleher1,2, Amanda C Shepherd1, Ian J Franklin1,3 and Alun H Davies1 
1 Academic Section of Vascular Surgery, Imperial College London 
2 Vascular Department, Royal Oldham Hospital 
3London Vascular Clinic 
 
Tristan R A Lane 
MRCS 
Academic Section of Vascular Surgery, Imperial College London 
 
Damian Kelleher 
FRCS 
Academic Section of Vascular Surgery, Imperial College London 
and 
Vascular Department, Royal Oldham Hospital 
 
Amanda C Shepherd 
MD 
Academic Section of Vascular Surgery, Imperial College London 
 
Ian J Franklin 
FRCS (Gen Surg) 
Academic Section of Vascular Surgery, Imperial College London 
And 
London Vascular Clinic 
 
Alun H Davies 
FRCS 
Academic Section of Vascular Surgery, Imperial College London 
 
Corresponding Author and for Reprint Requests 
Tristan Lane 
Academic Section of Vascular Surgery, Imperial College London 
4 North, Charing Cross Hospital, Fulham Palace Road, London, W6 8RF 
tristan.lane@imperial.ac.uk 
02033117335 
 
Short Title 
The AVULS Trial – Phlebectomy Timing 
 
Funding: 
This Research was supported by a Research Grant from the Graham Dixon Charitable Foundation and by the National 
Institute for Health Research (NIHR) Biomedical Research Centre based at Imperial College Healthcare NHS Trust and 
Imperial College London. The views expressed are those of the authors and not necessarily those of the NHS, NIHR or 
the Department of Health. 
 
 
Manuscript (including references and Figure legends)
Click here to download Manuscript (including references and Figure legends): AVULS - Submission v4 - Except Abstracts - Post Revision.doc 
2 
 
Ambulatory Varicosity avUlsion Later or Synchronised (AVULS): A 
Randomised Clinical Trial 
Tristan R A Lane1, Damian Kelleher2, Amanda C Shepherd1, Ian J Franklin1,3 and Alun H Davies1 
1 Academic Section of Vascular Surgery, Imperial College London 
2 Royal Oldham Hospital 
3London Vascular Clinic 
Introduction 
With the advent of endovenous ablation techniques, the treatment of the incompetent 
truncal veins has been intensively investigated with multiple studies showing benefit (1-3).  This has 
led to clinicians moving away from surgical ligation of the saphenofemoral junction and stripping of 
the great saphenous vein, towards less invasive options.  However the issue of residual varicosities 
has not been conclusively investigated and remains a matter of debate (4), (5). 
Varicosities can be treated at the same sitting as truncal veins, either with phlebectomy or 
foam sclerotherapy; alternatively treatment of varicosities can be delayed for a period, when, in a 
number of patients the need for treatment will be reduced. 
There are two schools of thought with regard to treating varicosities in those patients 
undergoing truncal vein ablation. The first suggests simultaneous truncal treatment and phlebectomy 
as a single procedure (6,7).  The second advises delayed phlebectomy after monitoring for varicosity 
regression. If still present, these varicosities or REVAS (REsidual Varicosities After Surgery) can be 
addressed with either ambulatory phlebectomies or foam sclerotherapy (8) . 
Previous work in laser ablation has shown that approximately 40% of patients with delayed 
phlebectomies require a second procedure, which was matched in a non-randomised cohort study in 
radiofrequency ablation (8,9).  Carradice et al. showed that there was no difference in QOL outcome 
between the delayed or simultaneous varicosity treatment. 
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Advocates of the first option suggest that immediate treatment of surface varicosities is 
advantageous in that it ensures patients are treated in a single session and reduces the varicosity 
reservoir. However, this may increase operative time (9) , and could be over-treating patients whose 
varicosities may regress. 
Avoiding potentially unnecessary phlebectomies reduces operative time and potentially 
outpatient discomfort.  However, a variable number of patients do come back with troublesome 
residual varicosities, which require secondary procedures. 
There are a number of variables that confound the picture.  Patient factors such as age, body 
habitus and mobility will influence the result of any intervention on the venous system. Patient 
preference and expectations, as well as operator experience, may have an effect on patient and 
operator satisfaction. Pain levels experienced have been assessed only in the Hull study, which 
showed no statistical difference in pain or return to normal activities (9) . 
The aim of this study is to ascertain the outcomes of delayed or simultaneous phlebectomy 
in the context of truncal vein ablation. 
Methods 
AVULS was a single centre randomised controlled trial with the aim of  recruiting 240 
patients into 2 arms.  Patients undergoing local anaesthetic endothermal ablation of incompetent 
truncal veins were randomised into two groups  one with simultaneous varicosity avulsion; and the 
other with delayed treatment of the varicosities. 
Ethical Approval and Trial Registration 
Ethical approval has been granted for the AVULS Trial by Brighton Research Ethics 
Committee Reference Number 11/H1107/3.  The trial is registered with Current Controlled Trials - 
ISRCTN76821539 (10) . 
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Patient Selection 
Consecutive patients presenting with symptomatic primary varicose veins due to reflux in 
the great saphenous vein (GSV) or small saphenous vein (SSV) were invited to participate. The study 
was set in the Local Anaesthetic Varicose Vein Unit (LAVVU) of the Department of Vascular 
Surgery at Charing Cross Hospital.  Patients were followed up for 12 months post-procedure, with 
repeated quality of life measures at 6 weeks, 6 and 12 months and technical success appraisal at 6 
months. 
Patients were eligible if they have single truncal vein incompetence and visible symptomatic 
varicosities (>3mm) in the distribution of that target vein. 
Patients were consented and completed quality of life questionnaires incorporating the 
Aberdeen Varicose Vein Questionnaire (AVVQ), EuroQol EQ-5D 5 level and EQ-VAS and Centre 
for Epidemiological Studies – Depression Score (CES-D).  The consenting clinician completed the 
Venous Clinical Severity Score (VCSS), Clinical Etiological Anatomical Pathological stage (CEAP), 
VDS and also the estimated number of avulsions required. 
Power Calculation 
Aberdeen Varicose Vein Questionnaire: 
Based on previous randomised clinical trials, an improvement of 10 points is predicted at 6 
weeks with a standard deviation of 10 in patients who have concomitant phlebectomies.  A 
difference of 5 points at 6 months is considered clinically significant.  At 90% power and 5% 
significance, 64 patients per arm would be required. 
Allowing for loss to follow-up and protocol violation, target recruitment was set at 120 per 
arm, or 240 in total 
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Reasons for declining AVULS 
Patients who did not want to participate in the AVULS study were invited to offer a reason 
for declining to enter the study. 
Randomisation 
Following consenting and recruitment patients were randomised into concomitant or 
delayed phlebectomy groups on the day of treatment.  Randomisation was via computerised 
allocation at a remote location provided by a randomisation service (Sealed Envelope, London, UK).  
Treatment 
Treatment was then performed according to standardised endovenous thermal ablation 
using radiofrequency ClosureFAST catheters under tumescent local anaesthetia using standard 
Covidien Venefit procedure (11)  and multiple stab phlebectomies according to treatment arm.  
Number of phlebectomies and length of treatment were recorded.  Phlebectomies were performed 
as previously described under local anaesthetic, using vein hook phlebectomy technique. 
The treatment was non-blinded as the use of phlebectomies cannot be hidden from either the 
practitioner or patient.  Patients then received standardised above knee class IIcompression hosiery 
(20-30 mmHg) for 2 weeks post-operatively. 
Follow-up 
Patients were seen in the research clinic at 6 weeks, 6 months and 1 year post-operatively.  
At each clinic visit, clinical review was completed as were the quality of life questionnaires. 
At the 6 week visit, the patient was assessed for the need for further intervention by an 
independent clinicians unaware of the initial treatment group.  Intervention was offered if both 
patient and clinician identified symptomatic residual varicosities (>3mm).  Full blinding was not 
possible due to residual healing wounds.  This was offered as either foam sclerotherapy or multiple 
stab phlebectomies under local anaesthetic, as per local protocol.  All further treatments were 
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completed as soon as possible after the 6 week visit and all before the 6 month visit.  Phlebectomies 
were performed under local anaesthetic in an identical manner to the simultaneous treatment, with 
compression hosiery for two weeks post treatment (12), (13).  Foam sclerotherapy was performed 
under ultrasound guidance according to standard empty vein technique using Air/Foam mix of 4:1 
and eccentric foam compression, compression bandaging and stockings for 2 weeks post treatment 
(14,15). 
At the 6 month follow-up a duplex ultrasound scan was completed to ensure closure of the 
treated truncal vein.  This was categorised as fully occluded, predominantly occluded (<5cm sections 
of colour flow), predominantly patent (>5cm sections of colour flow) and fully patent.  The duplex 
ultrasound was performed by an independent vascular scientist blinded to the treatment allocation. 
Primary Endpoint 
The primary endpoint of this study was disease specific quality of life improvement at 6 
months post procedure assessed by the AVVQ 
Secondary Endpoints 
• The need for further procedures over the 6 month period 
• Clinical disease severity assessed using the Venous Clinical Severity Score (VCSS) 
• Generic quality of life assessed using the EQ-5D 
• Anatomical success assessed with colour duplex at 6 months 
• Level of depression assessed using CES-D  
Statistical Methods 
All data was entered into a bespoke database created in Microsoft Access version 14 
(Microsoft, Redmond, Washington, USA).  Statistical analysis was performed on SPSS version 22 
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(IBM, Armonk, New York, USA), Prism version 6 (Graphpad, La Jolla, California, USA) and 
Wizard Pro version 1.3.5 (Evan Miller, Chicago, Illinois, USA). 
Results 
From April 2011 until November 2012, 393 consecutive patients presenting to the Charing 
Cross Local Anaesthetic Varicose Vein Unit for treatment were screened for inclusion in the 
AVULS trial and 221 patients were suitable.  The 172 patients ineligible for the trial included those 
with no visible varicosities but truncal reflux (88 = 22%), patients with visible varicosities but no 
truncal reflux (71 = 18%) and patients with mixed truncal disease with venous anatomy unsuitable 
for endovenous treatment (13 = 3%).  Of the 221 patients eligible, 101 patients consented to 
randomisation.  Of those refusing to participate in the trial, 95% gave wanting single sitting 
treatment as their reason.  The final trial sample was 26% of the screened population and 46% of 
the suitable population.  Recruitment was slower than anticipated and was stopped early in order to 
complete the 12-month follow-up of patients already enrolled with the available funding. 
The baseline demographics are shown in Table 1, and as can be seen the groups were well 
matched, with no significant differences:  Treatment characteristics are shown below in table 2.  No 
baseline differences were seen between groups.  All treatments were completed as per protocol. 
Primary Outcome - AVVQ 
Mean AVVQ decreased following treatment as shown by Figure 2.  The mean baseline 
AVVQ was 22.54 (standard deviation, sd, 12.40), decreasing to 13.57 (12.04) at 6 weeks, 11.19 
(10.08) at 6 months and 8.56 (7.83) at 1 year, which represents a symptomatic improvement of 62%. 
(p<0.001).  Mean change at 6 weeks, 6 months and 12 months was −8.86 (11.30), −10.00 (10.24) and 
−11.54 (7.76) respectively (negative change equates to an improvement in symptoms).  The 
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improvement in scores continued throughout follow-up, with that at 12 months being significantly 
better to that at 6 weeks (p=0.046). 
Both groups showed a significant improvement in symptoms from baseline at all time points 
(p<0.0001).  There was a significant difference seen at 6 weeks, with the simultaneous group 
showing a 5.48 point improvement (p=0.029).  However there was no significant difference at 6 
months or 12 months.  Table 3 demonstrates the AVVQ values. 
When assessed between patients who did not need any further treatment after 6 weeks there 
was no significant difference seen between the groups at any time point. 
When comparing the groups who did and did not need further treatment a large significant 
difference of 8.1 AVVQ points was found at 6 weeks (p=0.004).  Though those patients requiring 
Further Treatment remained at higher symptom scores throughout, this difference was not 
statistically significant at 6 months or 12 months and is demonstrated by Table 4.  Further treatment 
was completed before the 6 months review. 
The final comparison for the AVVQ quality of life score was between those in the delayed 
group who needed further treatment compared to the simultaneous group.  This showed a large 
significant difference at 6 weeks and 6 months in favour of simultaneous treatment.  This is shown 
in Table 5 and Figure  4. 
Secondary Outcomes 
Need for Further Procedure 
19 patient required further procedures, with 18 undergoing multiple stab phlebectomy and 1 
opting for foam sclerotherapy of residual varicosities. 
There was a significant difference in need for further treatment between the delayed and 
simultaneous groups - 18 (36%) required further treatment in the delayed group compared with 1 
(2%) in the simultaneous group (p<0.001). 
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The odds ratio and relative risk of patients in the delayed group requiring further varicosity 
treatment were 27.78 and 18.36 respectively (p<0.0001). 
There was no difference between estimated number of multiple stab phlebectomies required 
prior to intervention (9.76 vs 8.24, p=0.171) in the patient groups and there was no significant 
difference between the number of phlebectomies estimated as necessary prior to intervention and 
the number performed in patients requiring further treatment (9.0 vs 7.33, p=0.3479). 
All procedures were completed as soon as feasible after the 6 week review and no further 
procedures were needed after 6 months or 1 year. 
Technical Success 
At 6 months, 94% of patients had truncal vein complete ablation.  No patient needed truncal 
retreatment and no cases of complete failure were found.  6 patients had areas of open truncal vein 
>5cm in length.  There was no difference in treatment success between groups (p=0.849). 
Generic Quality of Life 
There was a significant improvement in generic quality of life as measured by the EQ-5D  
QOL from baseline to 6 weeks (0.691 to 0.820, p<0.0001) but not as measured by the EQ-VAS 
(76.24 to 79.45, p=0.157).  The significant improvement in EQ-5D QOL was maintained through to 
12 months however there were no further significant differences seen between time groups.  This 
improvement equates to a 21% improvement in QOL.  This is shown in Figure 5. 
Overall, EQ-5D results showed the same trends as found for the primary outcome of 
AVVQ. 
Between treatment groups there was a significant difference in EQ-5D QOL at 6 weeks 
(Delayed 0.773, Simultaneous 0.866, p=0.033) but this difference was lost as the follow-up 
progressed, as shown in Figure 6.  There was no significant difference seen between groups for the 
EQ-VAS score. 
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For those patients not requiring further treatment, there was no significant difference seen 
between treatment arms. 
Comparing those requiring further treatment to those not requiring further treatment 
showed a significant difference at 6 weeks, with those needing further treatment having a 
significantly worse QOL (0.719 vs 0.846, p=0.018).  This difference was not seen at 6 months or 12 
months.  
Comparing those in the delayed group who required further treatment to the simultaneous 
group shows a similar picture - a significant difference at 6 weeks in favour of simultaneous 
treatment (0.720 vs 0.866, p=0.024) however this difference in QOL was not seen at 6 months or 12 
months.  This is shown in Figure 7. 
Clinical Disease Severity 
CEAP 
CEAP is a non-reactive clinical staging measure, however, it does provide an overview of the 
cohort. 
Median CEAP at baseline was 4 (inter-quartile range 3-4), decreasing to 2 (2-4) at 6 weeks, 2 
(1-4) at 6 months and 1(1-3) at 12 months.  This was a significant improvement from baseline 
(p<0.0001), and is shown in Figure 8. 
This represents an improvement in clinical signs from venous eczema to thread veins at 1 
year. 
When looking at the simultaneous and delayed groups, there was a significant higher CEAP 
score in the delayed group at 6 weeks (p=0.006) and 6 months (p=0.003), however by 1 year this 
was no longer significantly different (p=0.117).  This is shown in Figure 9. 
This represents an improvement for the delayed group from venous eczema to varicosities, 
compared to from venous eczema to thread veins in the simultaneous group. 
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VCSS 
Treatment led to a significant reduction in VCSS from a baseline of 7.368 (2.556) to 3.011 
(2.193) at 6 weeks, 2.557 (2.319) at 6 months and 1.978 (2.390) at 12 months (p<0.0001).  This 
represents a 73% decrease in clinical score.  Patients continued to improve after 6 weeks, with 12 
month scores being significantly lower than 6 weeks score (p=0.031). 
Treatment groups were well matched at baseline (Delayed 7.696 versus Simultaneous  7.061, 
p=0.229) and showed a significant difference in VCSS levels at all follow-up points as shown in 
Table 6 and Figure 10 (p=0.001 at 6 weeks, p=0.012 at 6 months and p=0.011 at 12 months). 
When comparing those patients who needed no further treatment, a significant difference 
between the delayed and the simultaneous groups was seen at 6 weeks (3.72 vs 2.22, p=0.004), 6 
months (3.21 vs 1.90, p=0.022) and 12 months (2.83 vs 1.14, p=0.013), again in favour of the 
simultaneous group. 
Assessing those patients who did and did not require further treatment, no statistical 
difference was seen at any follow-up time-point.  At 6 weeks the further treatment group scored 
3.82 vs 2.8 (p=0.082), at 6 months scored 3.07 vs 2.34 (p=0.371) and at 12 months scored 2.27 vs 
1.80 (p=0.537). 
Finally, assessing the group of the delayed arm that required further treatment versus the 
simultaneous arm, a significant difference in favour of the simultaneous arm was found at 6 weeks 
(3.81 vs 2.26, p=0.006), but at 6 months (3.15 vs 1.90, p=0.080) and 12 months (2.27 vs 1.14, 
p=0.088)this was no longer significant (p=0.080 and p=0.088). 
Depressive Symptoms - CES-D 
CES-D results are tabulated in Table 7.  There was no significant difference seen between 
baseline and 6 weeks for the CES-D score, though there was a 24% reduction (p=0.0636).  There 
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was a significant improvement between baseline and 6 months (24%, p=0.0199).  However at 12 
months this difference had reduced and was not significant (17%, p=0.2657). 
No significant difference was seen during follow-up in the delayed group.  There was a 
significant improvement at 6 weeks in the simultaneous group (p=0.0361) but this was no longer 
significant by 6 months (p=0.0796) or 12 months (p=0.6600). 
No significant difference was seen between groups at any time point during follow-up 
(Figure 11). 
Complications 
Two episodes of superficial venous thrombosis occurred, one in each group.  No other 
complications were reported by patients.  No DVTs were recorded. 
Discussion 
Endovenous management of varicose veins in the outpatient setting is a successful and safe 
procedure with increasing uptake (16,17).  This study provides further evidence of excellent results 
with endovenous ablation at up to 1 year after treatment in both clinical (73% improvement) and 
disease specific QOL (62% improvement) scoring systems.  Additionally generic QOL scores 
improved by 21%.  Both simultaneous phlebectomy and delayed phlebectomy groups showed 
excellent overall improvements.  Minimal complications were seen, with only two SVT episodes 
observed, one in each group.  This study provides further evidence that both simultaneous and 
delayed treatment pathways are safe and feasible.  The improvements after treatment show a 
significant improvement in patient morbidity following outpatient treatment of a common 
condition.  Disease specific clinical and quality of life scores show greater improvement than generic 
quality of life scores as would be expected by a more sensitive tailored assessment, however a 20% 
improvement in quality of life post treatment of a single condition indicates excellent improvement. 
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The main finding of this study is that simultaneous treatment of incompetent truncal veins 
and varicosed tributary veins provides improved clinical outcomes which persist up to one year after 
treatment.  Quality of life values are improved at 6 weeks in both disease specific and generic scoring 
systems.  These changes normalise by 6 months after adjunctive treatment was completed.  The 
simultaneous group showed an improved VCSS score out to 1 year compared to the delayed group 
and even when comparing only those patients who did not require further treatment.  CEAP scores 
were significantly different at 6 weeks and 6 months between the two groups, however this measure 
is not designed to assess clinical change, and improvements in clinical score are slow to occur.  
Additionally, patients with lipodermatosclerosis or venous ulcers cannot improve beyond C4 
(venous skin changes) and C5 stages (healed venous ulcer) respectively.  Venous eczema however 
can resolve and is also termed C4 (C4a). 
Understandably, no significant difference was seen in the QOL tools, as these patients were 
happy with their outcome.  Most interesting is how the "under-treated" group fared - those in the 
delayed group who underwent further treatment.  In these 18 patients whilst the clinical score was 
no longer significantly different to the simultaneous arm after further treatment (p=0.080 at 6 
months and 0.088 at 12 months), the AVVQ remained signficantly worse until 1 year. 
Depression screening scores (CES-D) improved overall at 6 months by 24%, before 
regressing to 17% improvement, a non significant improvement on pre-treatment values.  
Interestingly, delayed patients displayed no significant difference in scores at the time points, with 
simultaneous patients only improved at 6 weeks.  This may indicate that patients experience a greater 
mental-health "bounce" from a larger procedure, and the improvement offered by delayed treatment 
is too gradual to be assessed with the numbers achieved in this study. 
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Patients undergoing delayed treatment in this study had a significantly higher rate of further 
intervention (36% vs 2%, Relative Risk 18.36).  Advocates of delayed phlebectomies cite "over-
treatment" as a prime concern (18), however in a time of austerity (19) one must also consider 
"under-treatment" and its sequelae as shown by this study's worse outcomes in those patients 
needing further treatment.  With recent long term cohort data indicating that superficial venous 
disease has a progressive nature (20-22), and good outcomes from ascending theory evangelists (23) , 
the fact that patients receive both better clinical outcomes and the treatment that they prefer with 
simultaneous treatment may become a key driver to better healthcare. 
This study provides further evidence that simultaneous treatment of truncal veins and 
varicosities leads to improved early disease specific quality of life with improved clinical status as 
found by Carradice et al in the previous randomised study specifically addressing this question (9).  
That study of 50 patients using laser ablation found that clinical severity (as assessed by VCSS) was 
not significantly different at 1 year, but did show early improvement in favour of simultaneous 
treatment.  Our present study replicates these outcomes with early QOL improvement but adds 
extended clinical improvement. 
The odds ratio of patients undergoing adjunctive procedures in the delayed phlebectomy 
group in the Carradice trial was 16.67 (66% in delayed group vs 4% in simultaneous group) with a 
relative risk of 16.67, which is in keeping with the risk profile seen in our current study.  In our 
study, patients who underwent delayed treatment had an Odds Ratio of 28.125 (p<0.0001) and 
Relative Risk of 18.360 (p<0.0001) of requiring further treatment, with 36% requiring further 
treatment compared to 2% in the simultaneous group.  It is interesting that despite a decrease in 
overall percentage requiring re-intervention the risk statistics are in fact increased.  The patient 
demographic reported by Carradice et al had a far lower disease burden than that reported in this 
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study (AVVQ 13 vs 23 and VCSS 4 vs 7.4).  This may be secondary to change in referral practice in 
the intervening 5 years or a different burden of disease in our local geographical area. 
This study was powered to detect a 5 point difference in AVVQ at 6 months between 
groups, and thus required a recruitment target of 128 patients with 100% follow-up.  Allowing for 
loss to follow-up, target recruitment was 240.  81% of recruited patients were follow-up up to the 
primary endpoint at 6 months.  A significant limitation of this study is the failure to reach target 
recruitment over the 18 month recruitment period.  The target was not achieved due to patient 
preference for single sitting treatment despite equipoise from the researchers and careful consenting 
for both the trial and the procedure - >50% of the suitable population refused randomisation due to 
a preference for simultaneous treatment.  At 6 weeks the difference in AVVQ was 5.48 and at 6 
months 3.47.  It is possible therefore that this lack of significance is a Type 2 error.  Alternatively, as 
all patients requiring further treatment would have both received and recovered from the second 
intervention by 6 months, it may not be possible to achieve this difference.  A clearer picture may 
have been found if a further review at 6 weeks post re-intervention had been undertaken.  Carradice 
et al. also set their reintervention review at 6 weeks, and reassessed at 3 months, finding the same 
early quality of life improvements as this trial.  Using a longer time delay such as 3 months between 
initial treatment and possible further intervention may have offered better differentiation between 
groups and comparison between trials. 
Operating time was not recorded in this study, however all patients participating in the trial 
were scheduled as ± phlebectomies and booked onto standardised morning lists in single slots.  The 
morning day case lists catered for a maximum of 6 patients per session, based on one surgeon 
completing all tasks (consent, positioning, preparation and treatment including ultrasonography).  
Those undergoing adjunctive procedures were booked into similar single slots, however previous 
work on anaesthetic time reduction in general anaesthetic cases has found that large reductions in 
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treatment time are required to allow extra case throughput (24,25) , due to the logistical time 
involved in moving, positioning and preparing the patient.  This is even more vital in the context of 
local anaesthetic procedures where the patient must not feel rushed. 
Initial adjunctive procedures were not completed with foam sclerotherapy, though this is 
standard in some centres (26,27) .  This may provide a more time-efficient option, especially as 
tumescentless ablation techniques become more accepted and commonplace, as phlebectomies 
would require further injections of local anaesthetic, rendering the major selling point of these new 
techniques obsolete. 
Conclusion 
This study lends further weight to the argument that one stage treatment is not only the 
patients preference but also in their best interests with improved early quality of life and prolonged 
improved clinical status.  The clinical improvement is upheld even in those in the delayed group who 
do not need further varicosity treatment. 
This study would therefore suggest that simultaneous treatment of truncal veins and 
varicosities represents the optimal management of patients with symptomatic varicose vein disease.  
However, larger scale studies are required to confirm these results. 
Further work into cost-effectiveness, operating time and pain profile would allow clear 
guidance on not only the patient's ideal treatment pathway, but also the most efficient. 
Crucially the final decision on treatment pathway remains with the clinician and the patient 
as both simultaneous and delayed pathways offer good outcomes overall with excellent complication 
profiles. 
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Figure Legends 
Figure 1: AVULS Trial Consort Diagram 
Figure 2:  Aberdeen Varicose Vein Questionnaire (AVVQ) over the course 
of treatment. 
Figure 3:  Aberdeen Varicose Vein Questionnaire (AVVQ) over the course 
of treatment showing delayed and simultaneous groups. 
Figure 4:  AVVQ values for the Delayed and requiring further treatment 
group and the Simultaneous group 
Figure 5:  EQ-5D QOL for total cohort over follow-up 
Figure 6: EQ-5D Generic Quality of Life Outcomes for Simultaneous and 
Delayed Groups 
Figure 7: EQ-5D QOL Outcomes for patients comparing Further treatment in 
the delayed group and the Simultaneous Groups. 
Figure 8:  Overall CEAP status of the treated cohort. 
Figure 9:  CEAP for the Delayed and Simultaneous Treatment Arms. 
Figure 10: Mean VCSS in Delayed and Simultaneous Treatment Groups 
Figure 11: CES-D Scores during follow-up for Delayed and Simultaneous 
Groups 
Table Legends 
Table 1:  Baseline Demographics 
Table 2:  Completed Treatment Details 
Table 3: AVVQ Results between groups 
Table 4: AVVQ for no further treatment needed and further treatment 
needed groups. 
Table 5:  AVVQ values for the Delayed and requiring further treatment 
group and the Simultaneous group 
Table 6:  VCSS Outcomes over duration of follow-up. 
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Table 7: CES-D Scores during Follow-up. 
 Overall Delayed Simultaneous 
Patients (n) 101 50 51 
M:F 44:57 22:28 22:29 
Age 52.9 53.9 52.0 
BMI > 30 24% 26% 22% 
BMI 28.28 29.13 27.52 
CEAP (Median) 4 4 4 
Maximal Vein Diameter 9.04 8.97 9.11 
AVVQ Baseline 22.52 21.80 23.20 
VCSS Baseline 7.56 7.80 7.30 
EQ-5D QOL Baseline 0.691 0.695 0.688 
EQ-5D VAS Baseline 75.68 74.76 77.30 
CES-D Baseline 11.68 12.26 11.14 
Table 1:  Baseline Demographics 
 
Table 1
 Overall Delayed Simultaneous 
Patients (n) 101 50 51 
Trunks Treated (Median) 1.10 (1) 1.08 (1) 1.11 (1) 
Cycles Completed (Median) 6.71 (7) 6.93 (7) 6.49 (6) 
Vein Length Treated (Median) 46.97 (49) 48.51 (49) 45.43 (42) 
Pre-Operative Estimated Phlebectomies (Median) 9.00 (8) 9.76 (10) 8.24 (6) 
Phlebectomies Completed (Median) 6.84 (6) - 6.84 (6) 
Further Phlebectomies (Median) 7.33 (9) 7 (9) 10 (10) 
Table 2:  Completed Treatment Details 
 
Table 2
AVVQ Overall Delayed Simultaneous Difference p 
Baseline 22.54 (12.40) 22.69 (11.67) 22.39 (13.17) 0.30 0.908 
6 Weeks 13.57 (12.04) 16.34 (12.62) 10.86 (10.91) 5.48 0.029 
6 Months 11.19 (10.08) 12.93 (11.05) 9.46 (8.80) 3.47 0.120 
12 Months 8.56 (7.83) 9.48 (9.61) 7.60 (5.43) 1.88 0.387 
Table 3: AVVQ Results between groups 
 
Table 3
AVVQ No Further 
Treatment Needed 
Further Treatment 
Needed 
Difference p 
Baseline 22.08 (12.38) 24.70 (12.63) 2.62 0.937 
6 Weeks 11.97 (11.18) 20.07 (13.53) 8.1 0.010 
6 Months 10.24 (9.86) 15.48 (10.26) 5.24 0.069 
12 Months 8.05 (6.98) 10.73 (10.96) 2.68 0.335 
Table 4: AVVQ for no further treatment needed and 
further treatment needed groups. 
 
Table 4
AVVQ Delayed & Further 
Treatment Needed 
Simultaneous 
Difference p 
Baseline 24.76 (13.04) 22.39 (13.17) 2.37 0.534 
6 Weeks 20.56 (13.77) 10.86 (10.91) 9.7 0.005 
6 Months 15.74 (10.59) 9.46 (8.80) 6.28 0.033 
12 Months 10.73 (10.96) 7.60 (5.43) 3.13 0.258 
Table 5:  AVVQ values for the Delayed and requiring 
further treatment group and the Simultaneous group 
 
Table 5
VCSS Overall Delayed Simultaneous Difference p 
Baseline 7.32 (2.55) 7.65 (2.59) 7.00 (2.50) 0.65 0.212 
6 Weeks 2.99 (2.191) 3.76 (2.18) 2.26(1.96) 1.50 <0.001 
6 Months 2.56 (2.356) 3.20 (2.45) 1.90 (2.09) 1.30 0.012 
12 Months 1.90 (2.234) 2.62 (2.46) 1.14 (1.72) 1.48 0.011 
Table 6:  VCSS Outcomes over duration of follow-up. 
 
Table 6
CES-D Overall Delayed Simultaneous Difference p 
Baseline 11.68 (10.32) 12.26 (11.41) 11.14 (9.29) 1.12 0.598 
6 Weeks 8.85 (10.14) 10.81 (10.53) 7.02 (9.53) 3.79 0.082 
6 Months 8.22 (9.07) 8.82 (8.96) 7.65 (9.26) 1.17 0.574 
12 Months 9.66 (10.02) 9.32 (8.16) 9.96 (11.58) 0.64 0.829 
Table 7: CES-D Scores during Follow-up. 
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 Figure 1: AVULS Trial Consort Diagram 
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 Figure 2:  Aberdeen Varicose Vein Questionnaire (AVVQ) 
over the course of treatment. 
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 Figure 3:  Aberdeen Varicose Vein Questionnaire (AVVQ) over 
the course of treatment showing delayed and simultaneous 
groups. 
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 Figure 4:  AVVQ values for the Delayed and requiring 
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 Figure 5:  EQ-5D QOL for total cohort over follow-up 
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Figure 6: EQ-5D Generic Quality of Life Outcomes for 
Simultaneous and Delayed Groups 
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Figure 7: EQ-5D QOL Outcomes for patients comparing 
Further treatment in the delayed group and the Simultaneous 
Groups. 
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Figure 8:  Overall CEAP status of the treated cohort. 
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 Figure 9:  CEAP for the Delayed and Simultaneous 
Treatment Arms. 
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Figure 10: Mean VCSS in Delayed and Simultaneous 
Treatment Groups 
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Figure 11: CES-D Scores during follow-up for Delayed 
and Simultaneous Groups 
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